HEM Pharma Unveils Cutting-Edge Bio-Manufacturing Facility in Sejong

On July 18, HEM Pharma, a leader in microbiome-based healthcare solutions, celebrated the grand opening of its advanced bio-manufacturing factory in the Smart Green Industrial Complex, Sejong Special Self-governing City. This milestone marks the beginning of full-scale operations aimed at revolutionizing the biotech industry.

Expanding Production Capabilities

The Sejong factory is a testament to HEM Pharma's commitment to innovation, featuring an integrated structure for the production of clinical samples for live biotherapeutic products (LBP), CDO services, and microbiome-based health functional foods. Spanning 11,594 square meters, the facility significantly boosts the company's production infrastructure.

Technological Advancements

With the introduction of a membrane bioreactor (MBR) continuous cultivation system, the factory achieves at least five times higher productivity than traditional methods, ensuring hygienic and efficient operations. The facility is also equipped with a quality and process management system designed to meet both KGMP and U.S. FDA standards, ready to address global clinical demands.

Future Prospects

HEM Pharma plans to expand its production capacity and continue its pioneering work in microbiome research, including the development of 'HEMP-001', a depression treatment candidate that has already received FDA approval for Phase 2 clinical trials. The company is also venturing into the phytobiome field, leveraging plant-derived phytochemicals for next-generation healthcare solutions.

A Vision for Global Healthcare

CEO Ji Yosep emphasized the factory's role in transitioning HEM Pharma from a technology 'preparer' to a 'realizer', positioning the company as a key player in the global healthcare market. The event was attended by representatives from major partners, including Amway Korea, Celltrion, and Cosmax, highlighting the collaborative spirit driving these innovations.